Purple Biotech Ltd
PPBTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Purple Biotech Ltd focuses on Biotechnology services and products. Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. The company carries a $2.8M market cap, placing it firmly in the micro-cap category. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Market Cap
$2.8M
Beta
-0.53
P/E (TTM)
—
P/E (Fwd)
-1.73
EPS (TTM)
$-47.64
EPS (Fwd)
$-1.01
ROE
-111.1%
ROA
-20.3%
Cash
$6.1M
Total Debt
$134,000
Free CF
-$4.9M
52W Change
-70.8%
Annual Financials
Cash vs Debt
Where PPBT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PPBT finished 39.26% below its 150-day moving average ($3.26) and 53.52% below its 200-day moving average ($4.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PPBT overbought or oversold?
At the September 3, 2026 close, PPBT's RSI(14) was 81.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Purple Biotech Ltd holds $6.1M in cash against $134K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$4.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -111.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
PPBT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing PPBT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.